Browse STK31

Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00069 Protein kinase domain
PF00567 Tudor domain
Function

-

> Gene Ontology
 
Biological Process GO:0006401 RNA catabolic process
GO:0019439 aromatic compound catabolic process
GO:0034655 nucleobase-containing compound catabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046700 heterocycle catabolic process
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:1901361 organic cyclic compound catabolic process
Molecular Function GO:0004518 nuclease activity
GO:0004674 protein serine/threonine kinase activity
Cellular Component GO:0001669 acrosomal vesicle
GO:0030141 secretory granule
GO:0097223 sperm part
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STK31 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between STK31 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18281482Colorectal Carcinoma; Gastric Carcinoma; Esophageal CarcinomaPromote immunity (T cell function); essential for immunotherapyReverse transcription-PCR analysis showed that STK31 gene expression levels in cancer samples were significantly higher (P < 0.0001) than those in normal samples. The STK31 gene was frequently expressed not only in colorectal cancer but also in gastric and esophageal cancer. Moreover, STK31 peptide was able to elicit specific CTLs and induced CTLs lysed either peptide-loading or endogenously STK31-expressing target cells. These results showed that the new methodology in this study facilitated identification of CT antigens and that STK31 may be a candidate for cancer immunotherapy against gastrointestinal cancer.
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STK31 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STK31 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2480.508
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1150.866
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.510.355
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0340.951
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3390.826
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5180.749
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.0610.135
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1330.349
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.1870.417
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1290.755
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1290.837
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.4360.025
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STK31 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.58.210.30.161
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.58.5100.275
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STK31. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STK31. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STK31.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STK31. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STK31 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STK31 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTK31
Nameserine/threonine kinase 31
Aliases TDRD8; SgK396; serine/threonine-protein kinase NYD-SPK; sugen kinase 396; tudor domain containing 8; Serine/ ......
Chromosomal Location7p15.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STK31 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.